BioNTech SE

Our vision: Harnessing the immune system’s power to turn science into survival.
Data Privacy:

[BioNTech SE @BioNTech_Group]

At #ASCO26, we presented interim data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating an investigational PD-L1 x VEGF-A bispecific immunomodulator in 1L squamous and non-squamous #NSCLC.

[BioNTech SE @BioNTech_Group]

At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: https://t.co/UHMZfMotjm

#BioNTech #WomensCancer #GynecologicOncology

[BioNTech SE @BioNTech_Group]

The candidate is being developed by BioNTech and OncoC4.

Join the proffered paper session at 3:35 pm CET in Auditorium A1.

[BioNTech SE @BioNTech_Group]

Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.

[BioNTech SE @BioNTech_Group]

Join the poster session at 1:00 pm CET in the Foyer.

[BioNTech SE @BioNTech_Group]

Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews

[BioNTech SE @BioNTech_Group]

At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.

👉https://t.co/zHKIDyC983

#nsclc #esclc

[BioNTech SE @BioNTech_Group]

📢 JPM 2026|Strategic areas of focus

Oncology milestones in 2026:
- 7 late-stage data readouts
- 6 Phase 3 clinical trial initiations expected
- Focus on high-incidence indications, such as lung and breast cancer

📰 https://t.co/YGlCsNE9dY
🎥 https://t.co/YGlCsNE9dY
#JPM2026

[BioNTech SE @BioNTech_Group]

Tomorrow at #SABCS25, Dr. Schmid will share the study design of the global phase 3 ROSETTA Breast-01 trial evaluating a PD-L1 x VEGF-A bispecific antibody plus chemotherapy in PD-L1 negative TNBC.

Join the poster session at 12:30pm CST in Exhibit Hall.

[BioNTech SE @BioNTech_Group]

🔬 At #SABCS25, we shared interim global Phase 2 data from our investigational bispecific antibody program in metastatic #TNBC with our partner @bmsnews

Learn more in our press release: https://t.co/38zpH2ETF3

#BreastCancerResearch #OncologyScience #BioNTech

[BioNTech SE @BioNTech_Group]

Tomorrow at #SABCS25, Dr. Schmid will present preliminary data from a global multicohort phase 2 trial of a PD-L1 x VEGF-A bispecific antibody plus chemotherapy for 1L/2L+ locally advanced/metastatic TNBC.

[BioNTech SE @BioNTech_Group]

Today, together with OncoC4, we announced data on an investigational selective Treg modulator candidate in patients with advanced sqNSCLC.

Learn more in our press release: https://t.co/LocWoYOElZ

#LungCancer #NACLC25

[BioNTech SE @BioNTech_Group]

Global interim Phase 2 data in extensive-stage small cell lung cancer presented at #WCLC25:

Investigational approach designed to target PD-L1 and VEGF-A in a single molecule.

Full PR: https://t.co/HAf3GEv8v1

[BioNTech SE @BioNTech_Group]

Visit us at Booth #106.

[BioNTech SE @BioNTech_Group]

Small cell lung cancer is a key focus at #BioNTech with multiple trials across disease stages. At #WCLC25, we share global interim Phase 2 data on our PD-L1xVEGF-A bispecific antibody candidate in extensive-stage small cell lung cancer.

[BioNTech SE @BioNTech_Group]

We are partnering with @bmsnews to jointly develop and commercialize our PD-L1xVEGF bispecific #antibody candidate BNT327. Combining our expertise, resources, and global reach, we aim to bring novel combination therapies to patients with #cancer. 🚀 https://t.co/bh0xVQCY17

[BioNTech SE @BioNTech_Group]

🔗 Highlights of our oncology programs to be presented at ASCO:  https://t.co/mXT4JNr9wY

[BioNTech SE @BioNTech_Group]

At #BioNTech, we’re looking forward to #ASCO25, presenting oncology pipeline progress: mRNA cancer immunotherapies, ADCs, and next-gen immunomodulators and targeted therapies.

🗓 May 30 – June 3 | Chicago
📍 Booth #35165

#CancerResearch #ImmunoOncology #OncologyInnovation